C97 Stock Overview
A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$8.24 |
| 52 Week Low | US$4.20 |
| Beta | -0.61 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 285.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| C97 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -0.02% |
| 1Y | n/a | -7.3% | 8.2% |
Return vs Industry: Insufficient data to determine how C97 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how C97 performed against the German Market.
Price Volatility
| C97 volatility | |
|---|---|
| C97 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C97 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine C97's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 101 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings.
Co-Diagnostics, Inc. Fundamentals Summary
| C97 fundamental statistics | |
|---|---|
| Market cap | €119.33m |
| Earnings (TTM) | €27.87m |
| Revenue (TTM) | €77.84m |
4.3x
P/E Ratio1.5x
P/S RatioIs C97 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C97 income statement (TTM) | |
|---|---|
| Revenue | US$78.22m |
| Cost of Revenue | US$10.00m |
| Gross Profit | US$68.23m |
| Other Expenses | US$40.23m |
| Earnings | US$28.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
| Earnings per share (EPS) | 0.83 |
| Gross Margin | 87.22% |
| Net Profit Margin | 35.80% |
| Debt/Equity Ratio | 0% |
How did C97 perform over the long term?
See historical performance and comparison